Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Derm CasesDermatology / Primary Care / Nail disease

Derm Cases · Dermatology / Primary Care / Nail disease

OSCE — dystrophic toenails and a pigmented band: onychomycosis, psoriasis, and melanoma red flags

An 8-minute OSCE station on distinguishing onychomycosis from nail psoriasis and nail lichen planus, confirming fungus before oral antifungals, first-line terbinafine dosing, and recognising single-band melanonychia with Hutchinson's sign as subungual melanoma.

8 minosce2 min readVerification in progress

Target exams

NEET-PGINICETUSMLEPLABMRCP
On this page
Study tools

Target exams

NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE station on distinguishing onychomycosis from nail psoriasis and nail lichen planus, confirming fungus before oral antifungals, first-line terbinafine dosing, and recognising single-band melanonychia with Hutchinson's sign as subungual melanoma.

Brief (to candidate)

A 58-year-old man has yellow-brown crumbling great toenails for 2 years and asks for “the fungus tablet.” On exam you also notice a new single dark longitudinal band on the left thumbnail with pigment on the proximal nail fold. You have 8 minutes to triage nail dystrophies, confirm fungus before oral therapy, dose first-line treatment, and act on melanoma red flags.

[5]

Candidate instructions

  1. Differentiate onychomycosis, nail psoriasis, and nail lichen planus clinically.
  2. State why mycologic confirmation is required before oral antifungals.
  3. Prescribe first-line oral terbinafine with duration and LFT monitoring.
  4. Recognise single-band melanonychia ± Hutchinson's sign as possible subungual melanoma.
  5. Name when nail matrix biopsy is mandatory.
[1]

Examiner checklist (mark each domain / 10)

DomainKey actions expected
Onychomycosis cluesDistal-lateral subungual yellow-brown thickening, subungual debris, onycholysis; often concurrent tinea pedis; ~50% of abnormal nails are fungal — not all dystrophy is fungus[2][4]
DifferentialPsoriasis: pitting, oil-drop (salmon patch), onycholysis with erythematous border, often multiple nails ± skin psoriasis; lichen planus: thinning, ridging, dorsal pterygium (irreversible scarring — treat urgently)[1][3]
Confirm before treatKOH, culture, or PCR before oral antifungals (hepatotoxicity, interactions, months of therapy)[2][4]
First-line drugTerbinafine 250 mg daily — 6 weeks fingernails / 12 weeks toenails; baseline (± mid-course) LFTs; alternatives itraconazole pulse or fluconazole weekly when indicated[2]
Melanoma red flagSingle longitudinal pigmented band, new/widening, adult (esp. pale skin), Hutchinson's sign (pigment on proximal/lateral nail fold) → subungual melanoma until proven otherwise[1]
Biopsy pathwayDigital block; matrix-centred punch or longitudinal matrix biopsy for depth; do not rely on shave of pigment alone for staging[1]
CommunicationExplain slow nail regrowth (months), recurrence risk, treat concurrent tinea pedis; urgent pathway for pigmented band

Model key actions

  • Confirm fungus before starting terbinafine 250 mg daily (12 weeks for toenails).[2]
  • Distinguish psoriasis/LP patterns so non-fungal dystrophy is not treated as onychomycosis.[1][3]
  • Escalate single-band melanonychia with Hutchinson's sign to matrix biopsy for melanoma exclusion.[1]

Common errors

  • Starting oral terbinafine on clinical “fungus nails” without KOH/culture/PCR.
  • Missing nail LP pterygium and delaying steroids until permanent nail loss.
  • Reassuring single-band melanonychia as racial/benign without red-flag assessment.
  • Shave sampling pigment without matrix depth for Breslow-capable histology.
  • Forgetting LFT counselling and concurrent tinea pedis treatment.
[1] [2] [3]
References5ShowHide
  1. [1]Hwang JK, Grover C, Iorizzo M, et al. Nail psoriasis and nail lichen planus: Updates on diagnosis and management. Journal of the American Academy of Dermatology, 2024.PMID 38007038
  2. [2]Lipner SR, Scher RK. Onychomycosis: Treatment and prevention of recurrence. Journal of the American Academy of Dermatology, 2019.PMID 29959962
  3. [3]Gupta MK, Lipner SR. Review of Nail Lichen Planus: Epidemiology, Pathogenesis, Diagnosis, and Treatment. Dermatologic Clinics, 2021.PMID 33745635
  4. [4]Gupta AK, Stec N, Summerbell RC, et al. Onychomycosis: a review. Journal of the European Academy of Dermatology and Venereology : JEADV, 2020.PMID 32239567
  5. [5]Shajil C, Kumari R. Surgical Matricectomy Versus Phenolization in the Treatment of Ingrown Toenails: A Randomized Controlled Trial. Dermatologic Surgery, 2023.PMID 36735804
PreviousOSCE — dual pathway skin cancer staging: melanoma biopsy/SLNB and high-risk cSCC risk stratificationDermatology / Surgical oncology / Skin cancer MDTNextOSCE — electrosurgery and curettage: modality choice, C&E technique, and device safetyDermatology / Procedural Dermatology